Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Amgen.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
368actual
Sites
124
Countries
Australia, Austria, Belgium +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-10 | actual | When the study began enrolling |
| Primary completion | 2026-07-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-23 | estimated | The whole study's end, after follow-up |
| First posted | 2022-10-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Eosinophilic Esophagitis
Interventions
- Biological: Tezepelumab
- Biological: Tezepelumab
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFHistologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels
measured Week 24
Change from baseline in DSQ (Dysphagia Symptom Questionnaire) score
measured Week 24
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed